Balyasny Asset Management
IBIO icon

Balyasny Asset Management’s iBio IBIO Stock Holding History

Balyasny Asset Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05M Buy
1,170,893
+159,938
+16% +$286K ﹤0.01% 1804
2026
Q1 		$1.92M Sell
1,010,955
-85,224
-8% -$198K ﹤0.01% 1798
2025
Q4 		$2.12M Buy
1,096,179
+1,085,779
+10,440% +$1.48M ﹤0.01% 1830
2025
Q3 		$8.61K Buy
+10,400
New +$7.99K ﹤0.01% 2839

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Balyasny Asset Management's IBIO Position: Q2 2026 in Review

Balyasny Asset Management increased its iBio (IBIO) stake by 16% in Q2 2026, buying an estimated $286K and bringing the position to 1,170,893 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

Balyasny Asset Management first reported a position in IBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.12M in Q4 2025. 55 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Balyasny Asset Management held 1,170,893 shares of iBio worth $2.05M as of Q2 2026.
  • Balyasny Asset Management bought 159,938 iBio shares in Q2 2026, an estimated $286K.
  • iBio made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1804 holding.
  • Balyasny Asset Management first reported a position in iBio in Q3 2025 and has held it in 4 quarters since.
  • Balyasny Asset Management's iBio position peaked at $2.12M in Q4 2025.
  • 55 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.